An expert in cellular medicine and biotech innovation, Dr. Yang currently serves as the CEO of Taiwan Bio. He graduated from the Department of Life Sciences at National Yang Ming Chiao Tung University, later pursuing a Master’s degree in Translational Medicine and Clinical Trial Design at Imperial College London, and earning a PhD from the University of Oxford, where he focused on translational immunology research. His work is dedicated to transforming academic achievements into therapies that benefit patients.

After returning to Taiwan, Dr. Yang founded multiple biotech companies, covering areas such as bispecific antibodies and technological development and applications of bioactive materials. He also served as a partner at the Flying Vest startup accelerator. Upon joining Taiwan Bio, he initially took on the role of Chief Operating Officer, focusing on technology transfer and internal R&D integration. He successfully developed the FAST CGT platform, leading the team in advancing gene-modified mesenchymal stem cells and regulatory T-cell technologies. Subsequently promoted to CEO, he actively drives international collaborations, propelling Taiwan Bio toward global markets and the shared vision of a “chronic disease-free era.”

With comprehensive experience in finance and corporate governance, Ms. Jhuang has assisted numerous Taiwanese companies with public offerings and is a recognized expert in the biotech industry’s financial accounting field. She graduated from Soochow University’s Accounting Department and earned a Master’s degree in Accounting from Chinese Culture University.

Since joining Taiwan Bio, Ms. Juang has aligned her efforts with the company’s strategy to expand into overseas markets, helping establish a U.S. subsidiary and building financial and internal control governance systems for a multinational corporation. She has also led the company’s public offering plans. Prior to joining Taiwan Bio, she held financial and corporate governance leadership roles at several publicly listed companies, specializing in financial accounting, corporate governance, and internal control system development, laying a solid foundation for Taiwan Bio’s internationalization and sustainable growth.

Leading Taiwan Bio’s New Drug R&D Department, Dr. Wu bears the mission of building the company’s core competitiveness. She plays a key role in facilitating technology transfer from external sources and integrating it with internal R&D capabilities, a critical factor in the success of the FAST CGT platform. After joining the company, Dr. Wu organized a comprehensive R&D team, establishing gene-editing technologies and applying them to the development of regulatory T-cell and mesenchymal stem cell therapies, creating Taiwan Bio leading and unique cell engineering technologies.

Dr. Wu holds a Bachelor’s degree in Life Sciences, a Master’s degree, and a PhD from the Institute of Genomics and Systems Biology at National Yang Ming Chiao Tung University. She conducted postdoctoral research at the Duke University Medical Center, specializing in gene regulation and gene-editing technology development related to tissue regeneration.

As the head of Taiwan Bio’s Business Development Department, Dr. Chien brings extensive experience across R&D, clinical trials, manufacturing, and commercial development in the cellular medicine industry. She specializes in drafting CMC (Chemistry, Manufacturing, and Controls) documents for cell therapies and regulatory affairs. Dr. Chien graduated from the Department of Life Sciences at National Tsing Hua University, earned a Master’s degree from the Institute of Biopharmaceutical Sciences at National Yang Ming Chiao Tung University, and obtained her PhD from the Institute of Life Sciences at the National Defense Medical Center, focusing on cancer development and treatment, accumulating deep academic research expertise.

Since joining Taiwan Bio, Dr. Chien has managed various CDMO (Contract Development and Manufacturing Organization) projects, ensuring client needs are met while overseeing the progress of the company’s own product development. She accelerates the commercialization of innovative outcomes and actively seeks international collaboration and licensing opportunities to expand the company’s global market presence.

As the head of Taiwan Bio’s Medical Research Department, Erwin oversees clinical trials, medical affairs, and regulatory affairs, bringing over 22 years of experience in clinical trials and medical research. He has worked with several international pharmaceutical giants and prominent Taiwanese publicly listed medical companies. Erwin specializes in establishing clinical research management systems, developing standard operating procedures, and conducting GCP (Good Clinical Practice) audits. He possesses extensive practical experience in designing and executing early-phase and pivotal clinical trials.

Erwin graduated from the Department of Pharmacy at National Taiwan University and earned a Master’s degree in Pharmacology from the same institution. He has served multiple times as a council member and supervisor of the Taiwan Association of Clinical Research, and as one of the few leaders with experience managing clinical trials in cellular medicine, he has made significant contributions to the development of Taiwan’s cellular medicine industry.